GAAP Earnings Results GAAP EPS was $0.22 per diluted share, versus $0.17 in the same quarter last year. GAAP operating income for the second quarter of fiscal 2025 increased 25% to $47.4 million ...

Valued at a market cap of $8 billion, Bio-Techne Corporation (TECH) develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and ...

Bio-Techne Corp. is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific ...

Bio-Techne Corp. topped $1 billion in full-year sales for the first time, its latest results showed Thursday, and the Minneapolis-based life science firm said it is beginning a two-year leadership ...

BERLIN (dpa-AFX) - Bio-Techne Corp. (TECH), a life sciences company, announced Tuesday that it has won a second claim of reverse engineering by Miltenyi Biotec B.V. & Co. KG, which may appeal the ...

Bio-Techne Corp. failed to get shareholder approval on its executive compensation plan. While the vote is nonbinding, a no vote is rare. Only 35% of shareholders supported the plan during the so ...

May 7 (Reuters) - Bio-Techne (TECH.O), opens new tab on Wednesday beat Wall Street estimates for third-quarter profit, driven by growth in its unit that provides proteins, antibodies and other ...

GAAP Earnings Results GAAP EPS was $0.14 per diluted share, versus $0.31 in the same quarter last year. GAAP operating income for the third quarter of fiscal 2025 decreased 42% to $38.7 million ...

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets ...